Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Boehringer’s Triple Combo Hypertension Drug Put on Hold by MHLW Advisory Panel
April 21, 2016
- Key Govt Panel Launches Discussions on New Growth Strategy
April 20, 2016
- Opdivo’s Fulminant Type 1 Diabetes Risk Re-Stressed in MHLW Safety Bulletin
April 20, 2016
- LDP Finalizes Proposal for Growth Strategy; Touches on CIN, Drug Discovery Seeds
April 20, 2016
- Sales Reps Top Source of Drug Safety Information for Both Clinics and Pharmacies: PMDA Survey
April 19, 2016
- Wholesalers Cited Urgent Deliveries as Major Concern: Ryukaikon
April 19, 2016
- Wholesalers’ Negative Primary Margins on Sales Level Off: Ryukaikon
April 18, 2016
- PMDA Had 58 Paid Advisory Sessions on Drug Development for Startups, Academia: FY2015
April 18, 2016
- Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
April 18, 2016
- Quake Brings Production Offline at 1 Out of 24 Firms in Affected Region: MHLW
April 18, 2016
- Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
- Dyslipidemia Risk Triples in Patients on Olanzapine: PMDA Epidemiology Study
April 15, 2016
- Expedited Review Systems Now in Place in 3 Major Markets, but How Are They Different?
April 15, 2016
- LDP Proposal for New Growth Strategy to Push “Clinical Innovation Network”
April 15, 2016
- New Scheme on Switch OTC Gets Underway
April 14, 2016
- MHLW to Issue Notification to Ensure Restricted Use of Repatha
April 14, 2016
- Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
- Chuikyo to Make Go or No-Go Decision on Drug Price Survey by Mid-2016
April 14, 2016
- MHLW Panels Approve Guidelines for Reporting Adverse Reactions to Hep B Vaccines
April 14, 2016
- Govt, Industry Agree to Boost Public-Private Policy “Dialogue” to Deepen Talks on Social Security Challenges
April 13, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…